RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Total current assets

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndTotal current assets (Million USD)YoY (%)
Dec 31, 202418,661-4.20%
Dec 31, 202319,479+22.63%
Dec 31, 202215,884+13.34%
Dec 31, 202114,015+43.31%
Dec 31, 20209,779+27.18%
Dec 31, 20197,689+19.26%
Dec 31, 20186,448+48.73%
Dec 31, 20174,335+36.31%
Dec 31, 20163,180+9.09%
Dec 31, 20152,915+34.49%
Dec 31, 20142,167+20.62%
Dec 31, 20131,797+49.00%
Dec 31, 20121,206+84.72%
Dec 31, 2011653+82.56%
Dec 31, 2010358

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)